1. Introduction {#sec0005}
===============

The porcine epidemic diarrhea virus (PEDV) is an enveloped positive-sense RNA virus in the *Coronaviridae* family ([@bib0410], [@bib0520]). The PEDV genome is approximately 28 kb in length, with seven overlapping open reading frames encoding the replicase (ORF1a, 1b) nonstructural proteins and the accessory protein ORF3, as well as the spike (S), envelope (E), membrane (M), and nucleocapsid (N) structural proteins ([@bib0300]). The S protein mediates specific receptor binding and membrane fusion to facilitate viral entry and contains major antigenic epitopes for neutralizing antibodies against PEDV ([@bib0655]). The E protein is a membrane protein which has been found to play a role in viral budding in other coronaviruses ([@bib0495]), while the M protein plays a role in viral assembly ([@bib0140]). Coronavirus N proteins bind viral RNA, providing structural scaffolding for viral transcription, replication and assembly ([@bib0425]). The replicase genes encompassing two-thirds of the genome (ORF1a and ORF1b) encode two polyproteins that are further processed by viral proteases into 16 nonstructural proteins (NSPs 1--16) important for viral replication ([@bib0300]). These proteins and ORF3 remain to be fully characterized.

The mechanisms behind PEDV pathogenesis remain largely unknown due to the challenges in propagating field isolates in cell culture and the lack of genetic tools for virus manipulation. Coronaviruses have genomes approximately 30 kb in length, the largest among RNA viruses, which present a significant challenge in engineering vectors for the generation of infectious clones as the distinction between natural and amplification-associated mutations and sequencing errors can be extremely difficult to pin down. In addition, attempts to set up reverse genetics systems have been hampered by the instability and toxicity of viral genomic sequences. Recently, however, a number of reverse genetics techniques have been developed for PEDV, promising to greatly accelerate research into the PEDV replication cycle and pathogenesis. The three techniques used are targeted RNA recombination, the bacterial artificial chromosome (BAC) system, and *in vitro* ligation. These approaches, along with their strengths and weaknesses, will be discussed in detail in this review, as well as a few alternative methods that have yet to be applied to PEDV. As appropriate cellular substrates are significant factors for successful virus rescue and propagation, we will also present an overview of cell lines that have been studied in the context of PEDV. We will then discuss some topics that can be further explored using reverse genetics technology, namely the role of trypsin in viral propagation, the study of receptors and attachment factors for viral entry, S protein variation and its implications, the significance of ORF3 and N proteins, and how reverse genetics may help overcome challenges in PEDV vaccine design.

2. Reverse genetics of PEDV {#sec0010}
===========================

2.1. Targeted RNA recombination {#sec0015}
-------------------------------

Targeted RNA recombination was the first reverse genetics system developed for coronaviruses, being first devised and refined for the generation of recombinant murine hepatitis virus (MHV) ([@bib0305], [@bib0320], [@bib0705]). This technique was subsequently applied to reverse genetics of other coronaviruses such as feline infectious peritonitis virus (FIPV) ([@bib0235]) and PEDV ([@bib0360]). Considering the complications involved in generating full-length cDNA clones of coronaviruses, this technique eliminates the need to clone the genome in its entirety, including the particularly troublesome replicase genes.

Generally, this technique involves intracellular recombination between full-length viral RNA (typically by infection) and a viral RNA fragment generated by *in vitro* transcription and containing genetic modifications that result in a selectable phenotype. Such phenotypes have included changes in temperature sensitivity and plaque size, as pioneered by Koetzner et al. ([@bib0305]). More recently, the use of S proteins that confer a very specific change in host cell tropism has been employed for greater ease in recombinant virus selection ([@bib0320], [@bib0315]). Overall, targeted RNA recombination takes advantage of the high rate of coronavirus RNA recombination during host cell infection ([@bib0330], [@bib0370], [@bib0405]) as well as strict host tropism for selection of complete recombinant viral genomes.

For PEDV, the approach used by Li et al. involved two stages: the generation of a recombinant PEDV with strict murine cell tropism, followed by selection for the final modified PEDV recombinant in Vero cells ([Fig. 1](#fig0005){ref-type="fig"} ) ([@bib0360]). A synthetic donor construct was first prepared encoding (a) the bacteriophage T7 RNA polymerase promoter for RNA transcription, (b) a segment of the ORF1b sequence for targeted recombination, (c) the MHV S protein in place of the PEDV S, and (d) the remaining downstream sequences, including ORF3, E, M and N. Chimeric virus was generated by RNA recombination after electroporation of PEDV-infected Vero cells with transcribed RNA from the construct. Recombinants carrying the MHV S gene (mPEDV) were selected by propagation in murine L cells. For the next stage, a second donor construct encompassing the same genomic region was prepared. This construct carried PEDV S to enable recombinant virus selection in Vero cells, although in practice, it need not be the same S gene as the original virus. Likewise, the remaining genes (ORF3, E, M, N) may be modified and, in the case of ORF3, removed entirely or replaced with a reporter such as luciferase. Electroporation of transcribed RNA into mPEDV-infected L cells followed by selection on Vero yielded the final recombinant virus.Fig. 1Genetic manipulation of the PEDV genome by targeted RNA recombination. An RNA fragment containing the S protein of MHV flanked by upsteam and downstream PEDV sequences was generated by *in vitro* transcription. Upon electroporation into PEDV-infected cells, recombination occurs between the ORF1b sequences, creating a chimeric PEDV with MHV S. PEDV S was reintroduced back to the genome in a second recombination event with *in vitro* transcribed RNA encoding PEDV S along with an ORF3 deletion. Figure adapted from Li et al. ([@bib0360]).Fig. 1

Essentially, this system allows highly flexible modification of the approximately 8 kb structural gene sequence at the 3′ end of the genome. The relatively short cloned donor segment facilitates sequence verification, and use of replication-competent virus as the basis for RNA recombination ensures virus rescue as long as modifications introduced into the donor construct are non-lethal. Swapping of S, ORF3, E, M and/or N genes enables studies into gene product function. And as ORF3 is considered an accessory protein, recombinant PEDVs with reporters in place of ORF3 can be created with this technique, allowing tracking of recombinant virus replication and spread, as well as facilitating quantification of viral growth. Targeted RNA recombination is an elegant solution to obstacles faced in cloning the replicase genes, and remains an option if problems in infectious cDNA cloning appear insurmountable.

The main drawback of this method is that it relies on replicase genes to generate the desired recombinant viruses, preventing modification and hence study of these essential genes. Its dependence on T7 RNA polymerase transcription means that the viral genetic sequence must be carefully assessed for potential cryptic transcription termination signals, and mutations must be carefully implemented to avoid detrimental effect to the virus. Additionally, *in vitro* selection of the recombinant virus is contingent upon the use of an S gene that is capable of mediating entry into Vero or other known target cells. Viruses carrying mutations that destroy receptor binding or fusion cannot be generated for testing hypotheses regarding cell entry. Similarly, lethal mutations in other regions will prevent recovery of recombinant virus. And even after recombinant viruses have been successfully generated, they may need to be plaque purified and screened, especially in cases where multiple mutations or gene swaps are desired, as a single recombination event is not guaranteed ([@bib0335]). An identification marker at the far 3′ end of the donor sequence can be used for selection ([@bib0305]), which would require analysis of clones by procedures such as sequencing.

2.2. Infectious cDNA clone generation using the BAC system {#sec0020}
----------------------------------------------------------

Due to the instability and toxicity of the replicase genes when propagated as cDNA in bacteria, it has been extremely challenging to generate a full-length infectious clone for coronaviruses. Application of BACs designed to accommodate large inserts over 300 kb in size ([@bib0480], [@bib0610]) and be maintained at very low plasmid copy numbers per cell (1--2 copies) has enabled engineering of infectious clones for porcine transmissible gastroenteritis virus (TGEV) ([@bib0010]), severe acute respiratory syndrome coronavirus (SARS-CoV) ([@bib0015], [@bib0550]), human CoV OC43 (HCoV-OC43) ([@bib0640]), FIPV ([@bib0030]), Middle East respiratory syndrome CoV (MERS-CoV) ([@bib0020]), and MHV ([@bib0200]). Similarly, we recently reported successful construction of the first PEDV infectious clone using pSMART-BAC ([@bib0265]).

The genome of the PEDV strain AVCT12 was synthesized as eight separate fragments with specific restriction sites for ligation and cloning ([Fig. 2](#fig0010){ref-type="fig"} ). Two fragments were combined at a time by three-way ligation into subcloning vectors until the full-length cDNA clone was reconstituted. The expression cassette of this full-length clone comprises, in this order, the CMV promoter, the PEDV genomic sequence flanked by the 5′ and 3′ UTRs, a 25-residue polyA tract, the hepatitis delta virus (HDV) ribozyme cleavage site, and the bovine growth hormone termination and polyA sequence (BGH). Flanking this entire expression cassette are transcription terminator sequences, one at either end, to reduce transcription from cryptic promoters and reduce toxicity to transformed bacteria. This precaution supports the stable maintenance of viral cDNA in the pSMART-BAC system. After the cloning process, however, bacterial transposon sequences (ATGGTACCG) were found to have integrated into the genomic sequence, confounding attempts to rescue the virus. This issue was successfully circumvented by propagating all cloning and subcloning vectors in competent *Escherichia coli* DH10B and diligent inspection of clone sequences.Fig. 2Construction of a PEDV infectious clone using the BAC system. The AVCT12 genome was divided into small fragments (A--H) and synthesized with native restriction site sequences designated in black, introduced restriction sites in green and deleted restriction sites in red. After fragment assembly, the full-length cDNA was ligated to pSMART-BAC containing transcriptional terminator sequences (T in orange) flanking both directions of the cloning site. Figure adapted from Jengarn et al. ([@bib0265]).Fig. 2

Virus recovery itself was performed by transfecting the pSMART-BAC-based infectious cDNA clone into the Vero E6-APN cell line for rescue and propagation, although a recent protocol modification to use human embryonic kidney (HEK) 293T cells for transfection prior to transfer to Vero E6-APN has resulted in improved rescue titers (unpublished observations). Rescued virus showed similar growth in cell culture to the parental AVCT12, suggesting that modifications made to facilitate the cloning process did not interfere with *in vitro* replication.

The major advantage of full-length infectious clones over targeted RNA recombination is that it allows manipulation of the entire PEDV genome. The eight-fragment system enables easy and separate modification of individual genes. Interestingly, the AVCT12 strain in particular has lost expression of its ORF3 gene due to deletion of the region containing the ORF3 start codon. It exhibits strong growth in Vero E6-APN culture, and can support expression of a transgene in place of the ORF3 gene. An AVCT12 construct carrying the fluorescent reporter gene mCherry has been created to facilitate tracking of virus replication and spread.

Although BAC-based infectious clones are extremely powerful and highly desirable tools for manipulation of the PEDV genome, it is not without its challenges. The construct design in itself requires careful planning in the selection of restriction sites for fragment assembly, and should the process necessitate the removal of native restriction sites or introduction of new ones, caution must be taken in their mutagenesis to avoid affecting viral replication. Additionally, we observed insertion of bacterial tranposons into the viral sequence after propagation in bacteria, so regular checking of sequence fidelity at every step during clone construction is critical. This need to recheck viral sequences at each cloning step is a major bottleneck for workflow, especially after the full-length cDNA assembly stage, and having accurate, verified sequence data for the original, infectious virus as a basis for comparison is absolutely vital for cloning success.

2.3. Infectious cDNA clone generation by *in vitro* ligation {#sec0025}
------------------------------------------------------------

Another approach for minimizing the impact of genomic instability and toxicity in bacteria is to avoid full-length clone propagation in bacteria altogether. With *in vitro* ligation, multiple fragments of viral cDNA encompassing the entirety of the viral genome are assembled in a stepwise manner *in vitro* and transcribed as full-length infectious RNA by T7 RNA polymerase. The full-length RNA is then electroporated into cells for virus production. This technique was first developed to simplify preparation of a TGEV molecular clone ([@bib0795]), and has subsequently been applied to the reverse genetics of other coronaviruses, namely MHV ([@bib0800]), infectious bronchitis virus (IBV) ([@bib0195], [@bib0790]), SARS-CoV ([@bib0805]), bat SARS-like CoV ([@bib0005], [@bib0045]), HCoV-NL63 ([@bib0180]), and MERS-CoV ([@bib0595]).

For PEDV, *in vitro* ligation was used to generate an infectious cDNA clone of the virulent North American strain PC22A ([@bib0040], [@bib0490]). Six cDNA fragments spanning the entire PEDV genome were designed with flanking class II restriction endonuclease sites for seamless and specific ligation (see assembly details in [Fig. 3](#fig0015){ref-type="fig"} ). Each fragment was inserted into a subcloning vector, with the 5′-most segment ligated to a T7 RNA polymerase promoter. The fragments were subsequently digested, ligated, and transcribed *in vitro* to generate full-length RNA transcripts of the virus. Infectious RNA was subsequently electroporated into Vero cells for recovery of infectious PEDV. N gene transcripts were also prepared and electroporated along with the genomic RNA as previously done with TGEV ([@bib0795]), where N was shown to be critical for efficient virus replication and spread. Such N supplementation has proven to enhance rescue of other coronaviruses as well ([@bib0790], [@bib0805], [@bib0800]) but has not been needed for DNA-launched virus production systems like the BAC approach, suggesting the importance of N-mediated encapsidation of coronavirus RNA for transcription initiation.Fig. 3Construction of a PEDV infectious clone using *in vitro* ligation. The genome of PC22A, a pathogenic strain of PEDV, was divided into six fragments, with the first and the last fragments carrying a T7 RNA polymerase promoter and polyA sequences respectively (indicated in gray boxes). Each fragment was flanked by recognition sites for the type II restriction enzyme SapI, which leaves unique overhangs at both 5′ and 3′ ends and allows directional ligation assembly of full-length cDNA fragments. Figure adapted from Beall et al. ([@bib0040]).Fig. 3

The *in vitro* ligation technique shares many strengths of the BAC system, such as ease in modifying the entire PEDV genome and insertion of alternative genes into the ORF3 expression cassette. Its engineering approach can also be applied to simplify cloning into BAC vectors, by circumventing the stepwise ligation process with a single *in vitro* ligation reaction. Furthermore, it also offers an alternative to the use of the BAC system by bypassing the need for a stable bacterial vector for the full-length cDNA clone. Instead, the cDNA is maintained as separate segments in smaller subcloning vectors. Toxicity of replicase gene fragments remains an issue even in subcloning vectors however, although it has been determined that splitting the genes at specific regions into separate fragments can help alleviate the problem ([@bib0595], [@bib0795], [@bib0800]). Design of cDNA fragments will need to work around this requirement.

This technique also amplifies certain weaknesses of the targeted RNA recombination approach, due to the sheer length of the RNA transcript. Fragment design will need to take potential transcription termination sites into consideration ([@bib0795]). And despite the low error rate of T7 RNA polymerase, specific errors have been associated with the enzyme ([@bib0175], [@bib0560]). The correctness of the full-length RNA used as the template for virus production is contingent upon the fidelity of the T7 RNA polymerase, may vary with each experiment, and cannot be verified prior to use.

2.4. Infectious cDNA clone generation in vaccinia vectors {#sec0030}
---------------------------------------------------------

Vaccinia vectors provide another alternative to the use of bacteria for maintenance and propagation of PEDV cDNA. A large DNA virus in the family *Poxviridae*, the vaccinia virus has a 185 kb genome that is capable of accommodating inserts of up to at least 26 kb in size ([@bib0450]). It encodes around 250 genes, containing the necessary replication machinery to enable viral transcription and replication in the cytoplasm. The virus is easy to grow to high titers, and efficiently infects a variety of cell types, both primary cells and cell lines of mammalian and non-mammalian origin, making it powerful as a gene vector for tissue culture. It was first applied to coronavirus reverse genetics by Casais et al., who used vaccinia as a platform for generation of recombinant IBV ([@bib0095]). Since then, it has been applied to reverse genetics of MHV ([@bib0130]), feline coronavirus (FCoV) ([@bib0675]), and SARS-CoV ([@bib0710]), as well as the study of HCoV-229E replicase genes ([@bib0685]). While there has been no report of the vaccinia vector being used for PEDV reverse genetics, the advantages it offers are worth consideration.

This approach is based on *in vitro* ligation of subgenomic cDNA fragments based on native or engineered restriction sites to generate full-length viral cDNA downstream of a T7 RNA polymerase promoter. While assembly steps vary with each report, the cDNA is ultimately ligated at the unique NotI site of the vNotI/tk vaccinia virus DNA ([@bib0450]). Some approaches first clone incomplete segments of genomic cDNA into vaccinia ([@bib0675], [@bib0710]), although full-length insertions of the 27-kb IBV and 31-kb MHV ([@bib0130]) genomes have been successful. The ligation reaction is then transfected into cells infected with fowlpox helper virus, which carries the necessary machinery for initiation of transcription. Recombinant vaccinia viruses are collected, and the DNA purified and used for T7 RNA polymerase-mediated transcription, either by *in vitro* transcription ([@bib0675]) or intracellularly in the presence of recombinant fowlpox virus expressing T7 RNA polymerase ([@bib0095], [@bib0710]). In the case of *in vitro* transcription, full-length coronavirus RNA will need to be electroporated back into cells to generate the final recombinant virus. While multiple steps are necessary for vaccinia vector-based reverse genetics, modifications to recombinant viruses can be achieved by homologous recombination, which, unlike the BAC and *in vitro* ligation systems described above, does not require reassembly of all component fragments.

2.5. Infectious cDNA clone generation by Gibson assembly {#sec0035}
--------------------------------------------------------

The Gibson assembly method is a relatively recent technology that enables assembly of DNA fragments up to several hundred kb in length ([@bib0210]). DNA fragments are designed with at least 20 overlapping bases at both 5′ and 3′ ends, and are ligated simultaneously in the absence of restriction digestion in a single-step, isothermic reaction. This is accomplished with three key components: (a) a 5′ exonuclease to generate recessed ends, (b) DNA polymerase to fill in the gaps after annealing of sticky ends, and (c) DNA ligase. While Gibson assembly has not been applied to coronavirus infectious clone construction, it has been used to successfully recover infectious clones of viruses such as porcine reproductive and respiratory syndrome virus (PRSSV) ([@bib0650]), dengue virus ([@bib0620]), and West Nile virus ([@bib0720]). Given that it eliminates the need for restriction site design, it may prove to be a very effective tool to complement *in vitro* ligation as well as cloning into BAC or vaccinia vectors.

As a ligation method, Gibson assembly does not inherently overcome the issue of sequence instability and toxicity. However, beyond being simply a tool for rapid assembly of cDNA, it can also circumvent the need for bacterial transformation as demonstrated by Suhardiman et al. ([@bib0650]) and Siridechadilok et al. ([@bib0620]), where Gibson assembly reactions were directly transfected into cells for virus production. By generating cDNA by RT-PCR from field samples, this approach can be extremely useful for rapid generation of viral clones that preserve viral sequence diversity. However, the complete elimination of bacteria propagation steps also prevents sequence verification and control prior to virus generation. Experimental variation is expected to be greater than the BAC and *in vitro* ligation methods if assembly of RT-PCR fragments are performed, and as such, this bacteria-free protocol is not recommended for biochemical studies without prior plaque purification and virus sequencing.

3. Cell lines for PEDV cultivation {#sec0040}
==================================

The development of a cell culture system for PEDV cultivation has been key to enabling PEDV research and is a critical component of reverse genetics rescue of PEDV. Successful *in vitro* propagation of PEDV was first reported in 1988 using Vero cells ([@bib0250]), which are derived from kidney epithelial cells of the African green monkey ([@bib0780]) and are now used widely in PEDV research. In this study by Hofmann and Wyler, inoculation of Vero cells with field-isolated PEDV of gut origin yielded detectable cytopathic effect involving formation of syncytia containing less than 10 nuclei ([@bib0250]). After three passages in cell culture, however, Vero infection resulted in much more extensive syncytia (up to 100 nuclei), indicating that a certain degree of adaptation must take place for field isolates to replicate well in culture. Indeed, the success rate of field isolate cultivation can be quite low in Vero cells, and the virus may gradually lose infectivity upon further passaging ([@bib0120]). These observations emphasize the need for cell lines allowing for less selective propagation of field isolates. Several traditional and newly established cell lines have, therefore, been examined for their permissiveness for PEDV replication. [Table 1](#tbl0005){ref-type="table"}, [Table 2](#tbl0010){ref-type="table"} provide a representative overview of cell lines that have been tested for PEDV propagation. While cells derived from species other than swine have shown susceptibility to PEDV ([Table 1](#tbl0005){ref-type="table"}), some porcine cells isolated from different organs were found to be non-permissive ([Table 2](#tbl0010){ref-type="table"}). One technical reason for the inability of porcine primary cells to support PEDV growth could be the standard practice of adding trypsin to promote replication, as primary cells tend to be hypersensitive to trypsin and detach rapidly, preventing efficient PEDV infection ([@bib0250]). Mechanistically, this may involve viral entry by field isolates and the question of receptor usage, which will be discussed in detail in a later section. Briefly, while several groups have highlighted porcine aminopeptidase N (pAPN) as the key receptor for cell entry of PEDV ([@bib0355], [@bib0385], [@bib0470]), the considerable number of non-porcine cell lines used for PEDV propagation suggests that other receptors could play a role in infection. Elucidation of the mechanisms underlying infection of field isolates would greatly advance development of optimal cell culture systems for PEDV propagation *in vitro*, as well as minimize cell culture adaptation that may significantly alter PEDV pathogenesis.Table 1Cells reported as permissive for PEDV propagation *in vitro.*Table 1CellCell descriptionPEDV strain (cell-adapted or field isolates)Cell maintenance mediumPost-infection mediumNoteReferenceVeroAfrican green monkey kidney cell line (CCL-81)V215/78 (field, Germany),\
Not specified (field, Belgium)EMEM, 30 mM HEPES, 10% FBS, 100 IU of penicillin, 100 μg/mL streptomycinEMEM, 0.3% tryptose phosphate broth, 0.02% yeast extract, 10 μg/mL trypsin([@bib0250])KPEDV-9 (cell-adapted)α-MEM, 5% FBS, antibioticsα-MEM, 0.3% tryptose phosphate broth, 0.02% yeast extract, 2 μg trypsin(Oh et al., 2004)ISU13-19338E (field, Indiana, US), ISU13-22038 (field, Iowa, US)MEM, 10% FBS, 2 mM L-glutamine, 0.05 mg/mL gentamicin, 10 units/mL penicillin, 10 μg/mL streptomycin, 0.25 μg/mL amphotericinMEM, 0.3% tryptose phosphate broth, 0.02% yeast extract, 5 μg/mL trypsin([@bib0120])PC168, PC170, PC173, PC177, PC179, PC180, PC182, PC21A and PC22A (field, Ohio, Michigan, Illinois and Iowa, US)DMEM, 5% FBS, 100 unit/mL penicillin, 100 μg/mL streptomycin, 0.25 μg/mL FungizoneDMEM, 100 unit/mL penicillin, 100 μg/mL streptomycin, 0.3% tryptose phosphate broth, 10 μg/mL trypsin([@bib0490])HLJBY (not specified)DMEM, 10% FBS, 100 units/mL penicillin, 100 units/mL streptomycinDMEM, 10 μg/mL trypsin([@bib0445])KPEDV-9 (cell-adapted),\
SM98LVec (cell-adapted)MEM, 10% FBSMEM, 10 μg/mL trypsin([@bib0500])Ohio VBS2 (field, Ohio, US)Not specifiedMaintenance medium, 5 μg/mL trypsin([@bib0385])YN144 (cell-adapted)DMEM, 10% FBSDMEM, 10 μg/mL trypsinCells are also permissive to lentivirus pseudotyped with PEDV S([@bib0745])Vero E6African green monkey kidney cell line (CRL-1586)CV777 (cell-adapted)DMEM, 10% FBSDMEM, 2.5 μg/mL of trypsinVero E6 shows contact inhibition([@bib0080])Vero-\
TMPRSS2Vero cells stably expressing TMPRSS2MK (cell-adapted)DMEM, 5% FBSDMEM, 10% tryptose phosphate broth, 2.5 μg/mL trypsin([@bib0605])IECsSwine small intestine epithelial cells (ileum)CV777 (cell-adapted)DMEM-F12, 10% FBSDMEM-F12, 2.5 μg/mL of trypsin([@bib0135])Shaanxi strain (field, China)DMEM-F12, 5% FBSNot specified([@bib0085])3D4Porcine alveolar macrophage cell lineKPEDV-9 (cell-adapted),\
SM98LVec (cell-adapted)RPMI 1640, 10% FBS, 10 mM HEPES, 1.0 mM sodium pyruvate, 0.1 mM nonessential amino acidsMEM, 10 μg/mL trypsin([@bib0500])MK-DIECDuck intestinal epithelial cell lineColorado strain (cell-adapted)1:1 of DMEM: mammary epithelial growth medium, 70 μg/mL bovine pituitary extract, 5 ng/mL human epidermal growth factor, 5 μg/mL insulin, 0.5 μg/mL hydrocortisone, 2% FBSDMEM, 0.3% tryptose phosphate broth, 0.02% yeast extract, 1% penicillin/streptomycin, 2.5-10 μg/mL trypsinCells endogenously express APN (immunofluorescent staining)([@bib0285])KSEK6Swine epithelial cell lineP5-V (cell adapted)Information not accessibleInformation not accessible([@bib0275])IB-RS-2Swine kidney cell lineP5-V (cell adapted)Information not accessibleInformation not accessible([@bib0275])PK15Pig kidney cell lineOhio VBS2 (field, Ohio, US)Not specifiedMaintenance medium, 5 μg/mL trypsin([@bib0385])YN144 (cell-adapted)DMEM, 10% FBSDMEM, 10 μg/mL trypsinCells endogenously express APN and are also permissive to lentivirus pseudotyped with PEDV S.([@bib0745])Huh-7Human liver cell lineYN144 (cell-adapted)DMEM, 10% FBSDMEM, 10 μg/mL trypsinCells endogenously express APN and are also permissive to lentivirus pseudotyped with PEDV S.([@bib0745])Ohio VBS2 (field, Ohio, US)Not specifiedMaintenance medium, 5 μg/mL trypsin([@bib0385])STPig testis cell lineOhio VBS2 (field, Ohio, US)Not specifiedMaintenance medium, 5 μg/mL trypsin([@bib0385])MRC-5Human lung cell lineOhio VBS2 (field, Ohio, US)Not specifiedMaintenance medium, 5 μg/mL trypsin([@bib0385])Tb1-LuBat lung cell lineOhio VBS2 (field, Ohio, US)Not specifiedMaintenance medium, 5 μg/mL trypsin([@bib0385])PK15-APNPig kidney cells exogenously expressing human or porcine APNRetrovirus pseudotyped with PEDV SNot specifiedNot specified, no trypsin added([@bib0385])MDCK-APNCanine kidney cells exogenously expressing human or porcine APNRetrovirus pseudotyped with PEDV SNot specifiedNot specified, no trypsin added([@bib0385])MARC-145African green monkey kidney cell line MA-104Colorado/2013 (field, Iowa, US)DMEM, 10% FBSDMEM, 0.3% tryptose phosphate broth, 0.02% yeast extract, 2 μg/mL trypsin 250([@bib0825])[^1]Table 2Cells reported non-permissive to PEDV *in vitro* or hypersensitive to trypsin.Table 2CellCell descriptionPEDV strain (cell-adapted or field isolates)Cell maintenance mediumPost-infection mediumNoteReferencePD5Porcine thyroid cell lineV215/78 (field, Germany),\
Not specified (field, Belgium)EMEM, 30 mM HEPES, 10% FBS, 100 IU penicillin, 100 μg/mL streptomycinEMEM, 0.3% tryptose phosphate broth, 0.2% yeast extract, 10 μg/mL trypsinNo cytopathic effect or viral protein synthesis detected([@bib0250])PK15Porcine kidney cell lineV215/78 (field, Germany),\
Not specified (field, Belgium)EMEM, 30 mM HEPES, 10% FBS, 100 IU penicillin, 100 μg/mL streptomycinEMEM, 0.3% tryptose phosphate broth, 0.2% yeast extract, 10 μg/mL trypsinNo cytopathic effect or viral protein synthesis detected([@bib0250])HRT18Human rectal tumor cell lineV215/78 (field, Germany),\
Not specified (field, Belgium)EMEM, 30 mM HEPES, 10% FBS, 100 IU penicillin, 100 μg/mL streptomycinEMEM, 0.3% tryptose phosphate broth, 0.2% yeast extract, 10 μg/mL trypsinNo cytopathic effect or viral protein synthesis detected([@bib0250])Fetal cellsPorcine primary and secondary cellsV215/78 (field, Germany),\
Not specified (field, Belgium)EMEM, 30 mM HEPES, 10% FBS, 100 IU penicillin, 100 μg/mL streptomycinEMEM, 0.3% tryptose phosphate broth, 0.2% yeast extract, 10 μg/mL trypsinCells damaged by trypsin activity([@bib0250])Vero 76African green monkey kidney cell line (CRL-1587)PC168, PC170, PC173, PC177, PC179, PC180, PC182, PC21A and PC22A (field, Ohio, Michigan, Illinois and Iowa, US)DMEM, 5% FBS, 100 unit/mL penicillin, 100 μg/mL streptomycin, 0.25 μg/mL FungizoneDMEM, 100 unit/mL penicillin, 100 μg/mL streptomycin, 0.3% tryptose phosphate broth, 10 μg/mL trypsinCells rounded by trypsin activity([@bib0490])MDBKBovine kidney cell lineYN144 (cell-adapted)DMEM, 10% FBSDMEM, 10 μg/mL trypsinNo viral protein synthesis detected (immunofluorescent staining)([@bib0745])CCL94Cat kidney cell lineYN144 (cell-adapted)DMEM, 10% FBSDMEM, 10 μg/mL trypsinNo viral protein synthesis detected (immunofluorescent staining)([@bib0745])BSRHamster kidney cell lineYN144 (cell-adapted)DMEM, 10% FBSDMEM, 10 μg/mL trypsinNo viral protein synthesis detected (immunofluorescent staining)([@bib0745])MDCKCanine kidney cell lineYN144 (cell-adapted)DMEM, 10% FBSDMEM, 10 μg/mL trypsinNo viral protein synthesis detected (immunofluorescent staining)([@bib0745])[^2]

4. Role of trypsin in PEDV propagation {#sec0045}
======================================

PEDV propagation *in vitro* requires considerations beyond selection of an appropriate cell line. While knowledge gained from the study of other coronaviruses, along with trial and error, has helped inform our approaches to PEDV cultivation, the complex factors involved in viral entry into host cells still need to be elucidated before we can develop more robust systems for PEDV cell culture.

One of the key determinants of host cell tropism is the S protein, a 180--220 kDa type I viral glycoprotein that determines viral tropism by mediating host cell entry and membrane fusion. The S protein of the prototype CV777 strain is 1383 amino acids long ([@bib0185]), although this length varies among strains as the protein is characterized by both extensive insertion and deletion mutations as well as substitutions.

Typically, type I glycoproteins are expressed as precursor proteins that are activated by proteolytic cleavage into two subunits, the N-terminal and the C-terminal subunits. Proteolytic cleavage is generally programmed by the presence of a cleavage site for host cell proteases such as furin at the interface between the two subunits, as seen with diverse viruses such as influenza virus ([@bib0645]), human immunodeficiency virus (HIV) ([@bib0240]), and MERS-CoV ([@bib0460]). This cleavage generally releases the fusion peptide, which in the cases of influenza virus and HIV is directly positioned at the N-terminus of the second subunit ([@bib0205], [@bib0625]). However, coronaviruses appear to have a second cleavage site within S2 that is required for activating the fusion peptide, as first indicated by studies of SARS-CoV S and labeled as S2′ ([@bib0050], [@bib0400]).

By homology to other type I and coronavirus envelope glycoproteins, the PEDV S protein can be divided into two subunits: the N-terminal S1 and the C-terminal S2. The S1 subunit contains the signal peptide (predicted to be residues 1--20 ([@bib0185])) and receptor binding ectodomain, while the S2 subunit is fusogenic, containing both the fusion peptide and transmembrane domain. However, for many alphacoronaviruses, including PEDV and TGEV, there is no furin-like cleavage site at the predicted interface between S1 and S2 ([@bib0185]), raising the possibility that cleavage may occur primarily at the S' site. Data gleaned from other coronaviruses such as SARS-CoV ([@bib0615]) and MHV ([@bib0565]) suggest that such cleavage may occur during the entry process. Observations from cell culture may not reflect the natural mechanism of PEDV infection, however, as the context during host animal infection is likely different. It is known that coronaviruses tend to be highly species- and tissue-specific, with viral tropism being generally associated with receptor distribution. Enteric tropism, such as that of PEDV, is associated with a trypsin-rich environment, and it is possible that *in vivo*, PEDV S cleavage is mediated by this less discriminating protease. CV777 isolated from pig intestinal perfusate appeared to present S in cleaved form, with a major 89 kDa band and minor 112 kDa and 129 kDa bands ([@bib0190]). Nevertheless, the exact nature of *in vivo* cleavage and protease susceptibility remains to be definitively determined.

Given such a context, the first successful cultivation of PEDV was dependent upon the presence of trypsin for continued virus passaging and growth ([@bib0250]). The Vero-trypsin system is now standard for culturing PEDV *in vitro*, with regular addition of trypsin required for efficient replication, likely due to trypsin inactivation by Vero cells ([@bib0280]). Robust replication is associated with the formation of extensive syncytia ([@bib0250]). Trypsin can be functionally replaced by the transmembrane type II serine protease 2 (TMPRSS2), as demonstrated by the propagation of PEDV in Vero cells stably expressing TMPRSS2 ([@bib0605]). This promising approach may allow greater exploration of trypsin-sensitive cell lines for isolating and culturing PEDV.

Interestingly, there have been rare reports of trypsin-independent PEDV strains, such as the highly cell-adapted DR13 ([@bib0360], [@bib0635]) and KPEDV-9 ([@bib0325], [@bib0515]), both of which were maintained in Vero cells for over 90 passages. In the absence of trypsin, these viruses do not appear to form syncytia ([@bib0360], [@bib0525], [@bib0755]). Similarly, our own experience with the reverse genetics of AVCT12 has revealed that virus rescued in transfected HEK 293T cells in the absence of trypsin are capable of initiating infection of Vero E6-APN without causing syncytia (unpublished observations). These results hint at the possibility that host proteases within the endosome may play a role in cleaving the S protein. Furthermore, the lack of syncytia supports the idea that the S protein is not cleaved during processing and trafficking to the host cell membrane, and is expressed in the inactive form at the cell surface.

Attempts to answer the various questions regarding the nature of PEDV trypsin dependence have been made using reverse genetics as a central tool for hypothesis testing. Recombinant PEDV carrying either S from the trypsin-dependent CV777 strain or the trypsin-independent DR13 were tested for the impact of trypsin on viral entry, with trypsin treatment after receptor binding noticeably increasing relative infection rates of CV777-S virus, and decreasing rates for the DR13-S virus ([@bib0755]). These results suggest that, like SARS-CoV ([@bib0420]), PEDV S cleavage by trypsin may occur at the receptor-binding step, possibly due to increased accessibility after receptor binding-induced conformational changes. The significance of receptor binding is supported by similar observations in a study by Park et al. ([@bib0515]). Trypsin treatment during viral adsorption, but not virus or cell pretreatment, resulted in mild increases in internalized virus and viral titer. This slight change may have been due to the use of KPEDV-9, which has been shown to be trypsin-independent ([@bib0325], [@bib0515], [@bib0525]). Interestingly, there is some evidence to suggest that trypsin may play a role during viral egress as well. Electron microscopy of PEDV-infected Vero showed large virion clusters on the cell surface, and increased extracellular viral titers induced by trypsin treatment could be inhibited by leupeptin ([@bib0400]).

Reverse genetics-derived PEDV with chimeric S genes have been used to further delineate the nature of trypsin cleavage of PEDV S ([@bib0755]). Trypsin dependence was mapped to the S2 region containing the fusion peptide and first heptad repeat. Of particular interest was the arginine at residue 890, the S' site directly upstream of the fusion peptide, as arginines or lysines are targets for trypsin digest. The importance of S' as a cleavage site was underscored when mutation of this region into a furin cleavage site rendered the resultant virus trypsin-independent and capable of replicating to low titers ([@bib0365]).

For trypsin-independent strains like the cell-adapted DR13, trypsin exposure decreases viral infectivity, strongly indicating changes in S conformation during cell culture adaptation that increase S susceptibility to trypsin and possibly enable cleavage and maturation by host cell proteases ([@bib0525]). Cell adaptation may thus result in changes to S structure, with ramifications for S antigenicity in the case of vaccine development, as well as our understanding of the functional structure of S and its mechanism for cellular entry. The ability to preserve natural determinants of entry and replication reinforces the status of reverse genetics as an invaluable tool for studying properties of field isolate-like PEDV.

5. PEDV receptor binding and cell attachment {#sec0050}
============================================

Despite how integral the elucidation of PEDV S function is to explaining the virus' tropism and pathogenicity, work focused on direct characterization of the S protein and its receptor usage has been relatively scarce. This is due, in part, to limitations in viral manipulation, although the growing availability of reverse genetics tools is expected to rectify this issue. Thus far, however, we have been relatively reliant upon the homology between PEDV S and that of other coronaviruses to guide our understanding.

Indeed, like TGEV ([@bib0145], [@bib0150]), PEDV has been shown to utilize pAPN as a receptor for host cell entry ([@bib0355], [@bib0485]). Initial studies detected a 150 kDa band when probing porcine enterocyte and swine testis (ST) membrane proteins with PEDV in a virus overlay protein binding assay (VOPBA) ([@bib0485]). The size of this protein coincided with pAPN, and direct virus--APN binding was found to be dose-dependent and susceptible to competition with anti-pAPN antibodies. Later, expression of a pAPN transgene was shown to enable the non-permissive Madin-Darby canine kidney (MDCK) cell line to support PEDV replication ([@bib0355]), demonstrating the functional role of APN in PEDV infection. Assessment of pAPN binding to the CHGD-01 strain-derived S1 protein fragments by flow cytometry and ELISA showed strong contribution of the region between amino acids 538--638 in enhancing APN binding. These results suggest that binding function is conferred by the C-terminal domain of S1 ([@bib0160]), similar to other coronaviruses such as the APN-binding TGEV and HCoV-229E ([@bib0065], [@bib0070], [@bib0215]) and the ACE2-binding HCoV-NL63 and SARS-CoV ([@bib0025], [@bib0375], [@bib0760]). On the other hand, a co-immunoprecipitation study using the strain KNU-0801 by Lee et al. suggested that the N-terminal region of S1 is responsible for mediating pAPN binding, with amino acids at the 25--55 positions resulting in noticeably higher levels of pAPN pulldown ([@bib0345]). Nevertheless, the notable differences in S1 fragment expression levels and the lack of comparison with N-terminal truncation fragments leave room for reconciling the results from these two reports. In either case, attempts to characterize S functional domains were limited to binding assays using S1 protein fragments. While these studies provide intriguing insight into the mechanism of S-mediated viral entry, they do not yet demonstrate functional receptor usage by these domains. Manipulation of PEDV S by reverse genetics should enable functional studies in the viral context, supplement our understanding of the binding data, and help account for the differences in experimental results.

Interestingly, while Vero cells are the most common cellular substrate used for isolating or propagating PEDV, the functional receptor has yet to be identified for this cell line. As PEDV appears capable of binding both porcine and human APN ([@bib0385]) and APN tissue distribution includes expression on kidney epithelial cells ([@bib0170]), there is a possibility that PEDV may recognize and utilize simian APN. Strangely, VOPBA analysis using the Korean KPEDV-9 strain to probe Vero membrane proteins did not reveal any bands of note, despite the strain being capable of replicating in Vero cells ([@bib0485]). Our own work with Vero E6 cells also indicated basal levels of APN hydrolytic activity of leucine *p*-nitroanilide ([@bib0265]), although direct comparison with a known APN-negative cell line was not examined.

More recently, however, heparan sulfate has been suggested to act as an attachment factor for PEDV on Vero cells, with ablation of heparan sulfate on the cell surface resulting in reduction of PEDV entry as well as decreased viral titers upon preincubation with heparin ([@bib0255]). High affinity for *N*-acetylneuraminic acid has also been identified by a glycan screen, and treatment of human and bovine mucins with neuraminidase was shown to reduce PEDV S1 binding in a dot blot hybridization assay ([@bib0385]). The ability to bind sugars is unsurprising, as this property is shared across viruses in the family *Coronaviridae*. By homology to other alphacoronaviruses such as TGEV, the sugar binding domain of the PEDV S protein is likely to reside in the N-terminus of the S1 subunit. Indeed, ELISA assessing the binding of S1 fragments to bovine mucin demonstrated stronger sugar binding activity in the N-terminal domain of S1, especially within the first 253 residues ([@bib0160]). Whether sugars act as functional receptors for PEDV infection of Vero cells and whether such receptor usage is mediated by the N-terminus of S1 remain to be conclusively demonstrated. Such data will also need to be reconciled with observations of Vero replication by PEDV with massive truncations in the S protein, namely Tottori2/JPN/2014, which has a 194-amino acid deletion from residues 23--213 (by CV777 numbering; [Fig. 4](#fig0020){ref-type="fig"} ) and was successfully cultivated in Vero cells ([@bib0415]), and PC177, which has a 197-amino acid deletion from residues 34--227 (CV777 numbering) directly arising from adaptation to Vero cells ([@bib0490]).Fig. 4S protein N terminus alignment. N-terminal amino acid sequences of the reference strain CV777 (accession number NP_598310), the S INDEL strain USA/Ohio851 (AHL38184), the N-terminal deletion strain Tottori2/JPN/2014 (BAR92898), and the prototype US virulent strain USA/Colorado/2013 (AGO58924) were aligned using Clustal Omega. Shaded sequences indicate defining insertion and deletion sites. Dashes (−) indicate deletions; asterisks (\*), amino acid conservation; colons (:), conservative mutations; dots (.), semi-conservative mutations.Fig. 4

Although work on TGEV S has formed a solid foundation for exploring the function of PEDV S, there are indications that PEDV S has a distinct functional structure. Firstly, the swine testis (ST) cell line, which is known both for its expression of pAPN and permissiveness for TGEV infection, has not been shown to support PEDV replication. Overexpression of pAPN in ST cells, however, resulted in PEDV-associated cytopathic effects and viral spread as shown by staining of PEDV N proteins ([@bib0470]), suggesting the possible significance of receptor density or other requirements in receptor usage. In contrast, TGEV infection of ST cells overexpressing APN showed decreased production of TGEV virions ([@bib0155]). TGEV S-pseudotyped lentiviruses have also been shown to infect the feline kidney cell line CCL94 ([@bib0745]) and the virus uses feline APN as a receptor, unlike PEDV ([@bib0695], [@bib0700]). Given the distinctive properties of PEDV S and the current availability of reverse genetics systems, we expect that more details regarding this protein and its unique functional structure will be forthcoming.

6. PEDV S variants {#sec0055}
==================

After the initial isolation of PEDV as the causative agent of a type of porcine diarrhea in Belgium in 1978 ([@bib0545]), the virus has been associated with relatively mild outbreaks in Europe and sporadic epidemics in Asia. Emergence of a highly virulent strain in China in 2010 ([@bib0660]), however, has been followed by a resurgence in severe PEDV outbreaks, including the first outbreak on the American continent in 2013. Increased surveillance of circulating PEDV strains has resulted in the identification of novel S variants, with most of the variation located in the N-terminus of the S protein. The nature of the evolutionary pressure on this region along with the impact of these variations on viral life cycle and pathogenicity are being gradually elucidated, and widespread application of reverse genetics would further help clarify observations in the field.

Recently sequenced isolates tend to cluster together by both S and whole genome analyses ([@bib0350]), and share a 4-amino acid insertion at residue 58, a 1-amino acid insertion at residue 135 and a 2-amino acid deletion at residue 156 (see USA/Colorado/2013 as the representative sequence, [Fig. 4](#fig0020){ref-type="fig"}), according to CV777 numbering. These sequences represent the bulk of global epidemic PEDV strains currently detected in circulation.

Among these isolates, however, investigators have also been detecting variants containing a number of insertions and deletions relative to these predominant strains. USA/OH851 was described to show 99% genetic identity at the whole genome level to other strains detected in the United States after the 2013 outbreak, but closer identity to the Chinese CH/HBQX/10 ([@bib0830]) in the S1 region ([@bib0740]). This report was followed by isolates from Indiana, Iowa, Minnesota and Ohio ([@bib0490], [@bib0730]). Closely related strains have also been reported in Europe, namely France (FR/001/2014 to FR/003/2014) ([@bib0230]), Germany (GER/L00719/2014 and GER/L00721/2014) ([@bib0245]), Portugal (Portugal 2015) ([@bib0455]), Belgium (15V010/BEL/2015) ([@bib0680]) and the Netherlands (NL/GD001/2014, NL/GD002/2014). These strains, currently termed S INDEL strains, have lost the aforementioned insertions and deletions, a throwback to CV777, early isolates and vaccine strains such as SM98-1 and DR13 (see OH851 and CV777 as representative sequences, [Fig. 4](#fig0020){ref-type="fig"}) despite sequence divergence in the rest of the genome. Survey of the 754 S1 sequences available in the GenBank database indicate greater circulation of strains containing this INDEL pattern than has been noted previously in literature ([Table 3](#tbl0015){ref-type="table"} ). These observations are suggestive of recombination events with vaccine strains, and it is certainly curious to note that such recombinants have been preserved in the virus gene pool.Table 3List of strains with S INDEL pattern and their accession numbers in order of collection date.Table 3StrainAccessionCollection DateCollection LocationCV777NP_5983101977Belgium83P 5BAK329381982--1983JapanCH/SAEQ550041986ChinaBr1/87CAA809711987Great BritainKPEDV-9AHJ110401997South KoreaChinju99AAN86621(2002)South KoreaJS 2004 2AAT752982004ChinaDR13ABG78322(2006)South KoreaLZCABM64776(2006)Lanzhou, ChinaLBJ/03ABJ51939(2006)Heilongjiang, ChinaDXABS72123(2007)Gansu, ChinaHC070225AKS26489February 2007Taiwanvirulent DR13AFE859622009South KoreaItaly/7239/2009ALR84908January 2009ItalyMKAB548624(2010)JapanCH/HBQX/10AFV592402010ChinaAVCT12BAR73378January 2010ThailandCH/BJSY/2011AFJ970362011ChinaCH/FJND-1/2011AER105162011ChinaCH/FJND-2/2011AEQ928532011ChinaCH/JL/2011AFJ970392011ChinaCH/JLGZL/2011AFJ970382011ChinaCH2AFL026252011ChinaCH3AFL026262011ChinaCH4AFL026272011ChinaCH5AFL026282011ChinaCH6AFL026292011ChinaCH7AFL026302011ChinaSC-LAGU137892011Sichuan, ChinaCH22-JSAFM55054July 2011Jiangsu, ChinaItaly/178509/2014ALR84952July 2011ItalyItaly/200885/2014ALR84953July 2011ItalyHNZZAFJ54340August 2011ChinaCH-HKC-08-2011AFR11480August 2011ChinaCH13-GXAFM55052September 2011Guangxi, ChinaCH9-FJAFM55051September 2011Fujian, ChinaAH-MAHG97559October 2011Anhui, ChinaCH-STC-12-2011ALD19721December 2011ChinaJS2008AGD98685(2012)ChinaCH/FJXM-02/2012AFP252012012ChinaCH/AHHF/2012AFO428622012ChinaCH/YNKM/2012AFO428612012ChinaSD-MAFX98013February 2012Shandong, ChinaCH/GD-01/2012ALA15706March 2012Guangdong, ChinaCH/GD-05/2012ALA15710December 2012Guangdong, ChinaCH/GD-06/2012ALA15711December 2012Guangdong, ChinaGDS03BAO045902013Guangdong, ChinaGD10AKP167592013Guangdong, ChinaGD11AKP167602013Guangdong, ChinaGD13AKP167622013Guangdong, ChinaKDGN13DJAJD096002013South KoreaKDJN13_1003SWAJD096012013South KoreaCHM2013AJH769572013ChinaCH-GMB-02-2013AGO597892013ChinaCH/GD-08/2013ALA15733January 2013Guangdong, ChinaCH/GD-10/2013ALA15713January 2013Guangdong, ChinaCH/GD-15/2013ALA15718January 2013Guangdong, ChinaCH-WTC1-02-2013ALD19704February 2013ChinaCH/GD-11/2013ALA15714February 2013Guangdong, ChinaCH/GD-12/2013ALA15715February 2013Guangdong, ChinaCH-XLC-03-2013ALD19703March 2013ChinaCH/GD-13/2013ALA15716March 2013Guangdong, ChinaUSA/Indiana12.83/2013AID56667June 2013Indiana, USAUSA/Minnesota52/2013AID57081June 2013Minnesota, USAUSA/Iowa23.57/2013AID56751October 2013Iowa, USAUSA/Minnesota58/2013AID56787November 2013Minnesota, USAHawaii/39249/2014AKO63237November 2013Hawaii, USACH-GLC-2013ALV66172November 2013ChinaCH/GD-17/2013ALA15720November 2013Guangdong, ChinaCH/GD-18/2013ALA15721December 2013Guangdong, ChinaMYZ-1/JPN/2013BAT33329December 2013Miyazaki, JapanUSA/Iowa106/2013AID57027December 2013Iowa, USAUSA/Iowa107/2013AID57033December 2013Iowa, USANJAIC83850(2014)ChinaZK_OBAR733832014JapanGD19AKP167682014Guangdong, ChinaGER/L00719/2014CDW772132014GermanyGER/L00721/2014CDW772052014GermanyCH/GD-21/2014ALA15724January 2014Guangdong, ChinaCH/GD-22/2014ALA15725January 2014Guangdong, ChinaOH851AHL38184January 2014Ohio, USAUSA/Ohio126/2014AID57069January 2014Ohio, USAUSA/Minnesota187/2014AKJ21701January 2014Minnesota, USAHUA-PED55AJL35174January 2014VietnamHUA-PED58AJL35175January 2014VietnamHUA-PED60AJL35176January 2014VietnamHUA-PED63AJL35177January 2014VietnamHUA-PED67AJL35178January 2014VietnamHUA-PED68AJL35179January 2014VietnamCH-STNG-2014ALV66161January 2014ChinaKCH-1/JPN/2014BAT33317March 2014Kochi, JapanKCH-2/JPN/2014BAT33323March 2014Kochi, JapanKNU-1406-1AIR95864March 2014South KoreaKNU-1406-2AIR95870March 2014South KoreaKNU-1406-3AIR95871March 2014South KoreaKNU-1406-4AIR95872March 2014South KoreaOKY 1/JPN/2014BAT33335March 2014Okayama, JapanSQ2014AKP99781March 2014Jiangsu, ChinaSC1402AJW67223March 2014ChinaCZ2014AMB20700April 2014ChinaEAS1AKH45326October 2014ThailandEAS2AKH45332October 2014ThailandNL/GD001/2014AKU46226November 2014NetherlandsCH-SHC-12-2014AKN45975December 2014ChinaCH/GD-26/2014ALA15729December 2014Guangdong, ChinaCH/GD-28/2014ALA15731December 2014Guangdong, ChinaCH/NMG/XLGLALJ33145December 2014ChinaCH/HNYF/14ALB08472December 2014Henan, ChinaFR/001/2014AKE47378December 2014FranceNL/GD002/2014AKU46227December 2014NetherlandsHLJBYAKJ85723(2015)China15V010/BEL/2015AKC34872January 2015BelgiumCH-HFEC-01-2015AKN45968January 2015ChinaCH-XBC-01-2015AKN45979January 2015ChinaCH-YGC-01-2015AKN45980January 2015ChinaCH-ZWBZa-01-2015AKN45982January 2015ChinaCH-ZWC-01-2015AKN45984January 2015ChinaCH/HNQX-3/14ALF39589January 2015Henan, ChinaCH-JPYC-02-2015AKN45971February 2015ChinaCH/NMG/WLCBALJ33144February 2015ChinaSLO/JH-11/2015ALU34112September 2015SloveniaCH-XDC2-2015ALV66166March 2015China[^3]

Particularly intriguing is that a number of these recent INDEL strains appear to exhibit decreased virulence relative to circulating non-INDEL strains ([@bib0230], [@bib0380], [@bib0740], [@bib0775]), albeit to differing degrees. Unfortunately, these results are difficult to compare and interpret, due to variations in genomic background, cell culture adaptation, dosage, and animal characteristics. Application of reverse genetics for the generation of these S INDEL mutations would enable analysis of their impact in isogenic viruses under more uniform conditions.

Major deletions in the S gene have also been reported in Korea (MF3809/2008/South Korea) ([@bib0530]), Japan (Tottori2/JPN/2014) ([@bib0415]), and the United States (PC177) ([@bib0490]). MF3809 is characterized by a 204-amino acid deletion in the C-terminus of S1 (residues 713--916) and exhibited decreasing viral RNA after passaging in Vero cells ([@bib0530]). Tottori2, on the other hand, has a 194-amino acid deletion in the N-terminus of S1 and was capable of adapting to Vero culture ([@bib0415]) ([Fig. 4](#fig0020){ref-type="fig"}). The 197-amino acid deletion in PC177 is, however, understood to have occurred as a result of adaptation to Vero cells, and it is capable of growing to titers similar to non-deletion variants through at least 8 passages ([@bib0490]). Such a significant deletion of the S gene has already been observed with TGEV, where a 224-amino acid deletion in the S1 N terminus yielded the antigenically distinct porcine respiratory coronavirus (PRCV) that targets the respiratory tract of swine ([@bib0075], [@bib0570]). The deleted region encodes the sugar-binding domain ([@bib0310], [@bib0590]) and is thought to account for the loss of enteric tropism ([@bib0035], [@bib0310], [@bib0340]). It is tempting to speculate that the INDEL mutations and the large S deletions, localized to the N-terminus of S1, may alter receptor or sugar binding domains, affecting efficiency or selectivity of receptor binding and usage. Reverse genetics will be invaluable for fine delineation of the determinants of entry, tropism and pathogenesis encoded in these regions.

7. ORF3 function and cell adaptation {#sec0060}
====================================

The PEDV ORF3 protein is encoded by subgenomic mRNA located between the S and E genes. It is an accessory protein 224 amino acids in length and is shared between alphacoronaviruses including the bat coronavirus (BtCoV), HCoV-229E, HCoV-NL63 and TGEV ([@bib0815]). PEDV ORF3 is characterized as a transmembrane protein using SwissProt His, comprising at least 3 transmembrane domains (TM): TM1 (Q40--F60), TM2 (Y69--Y88) and TM3 (A95--F111) ([@bib0725]). The alignment of amino acid sequences from different ORF3 proteins and their homologs across the alphacoronavirus genus showed a similar TM pattern ([Fig. 5](#fig0025){ref-type="fig"} A) regardless of the low amino acid sequence conservation between them ([Fig. 5](#fig0025){ref-type="fig"}B).Fig. 5Sequence comparison of ORF3 homologs among coronaviruses. (A) Amino acid alignment of ORF3 and its homologs from PEDV, BtCoV, HCoV-NL63, HCoV-229E, TGEV and SARS-CoV. Shaded sequences indicate transmembrane domains. Dashes (−) indicate deletions; asterisks (\*), amino acid conservation; colons (:), conservative mutations; dots (.), semi-conservative mutations. (B) Rooted phylogenetic tree with branch length (UPGMA) of ORF3 and its homologs.Fig. 5

ORF3-like genes of the various coronaviruses are highly variable, with insertions and deletions occasionally resulting in deleted or truncated proteins. Most mutations occur during extensive passaging of the virus in cell culture and some have been correlated with viral attenuation. One study reported attenuation of TGEV virulence after serial passaging in cell culture ([@bib0765]). Sequence analysis of the S gene, which was expected to be the primary determinant of attenuation and cell culture adaptation, revealed mostly identical amino acid sequences between the original and serially passaged viruses. Interestingly, the ORF3 from the serially passaged virus was shorter than that of the virulent original. Similarly, a study comparing attenuated and pathogenic PEDV also found a 51-nucleotide deletion in the ORF3 gene of attenuated vaccine strains, including attenuated DR13, KPEDV-9 and P-5V ([@bib0510]). In addition, KPEDV-9, which had undergone 93 passages in Vero cells, exhibited reduced pathogenicity in neonatal pigs and was described as safe in pregnant sows ([@bib0325]). Therefore, it has been hypothesized that ORF3 truncation may affect PEDV pathogenesis.

However, not all ORF3 truncations have been associated with reduced pathogenicity. Recently, analysis was performed on the ORF3 of 27 field samples collected from different farms in Fujian, China, between 2010 and 2012 ([@bib0115]). These ORF3 exhibited notable heterogeneity and could be divided into 2 groups. Group 1 was composed of 26 viruses with full-length ORF3 (224 amino acids in length) and group 2 had the one strain (P55) with an ORF3 truncation (92 amino acids in length) shared with four selected ORF3 reference sequences (truncated-ORF3 CV777, CH/GSJIII/07, truncated-ORF3 CH/BJ/2011, truncated-ORF3 DBI865, and Zhejiang-08). Despite the truncated ORF3, the virulence of P55 did not differ from that of the isolates in group 1. A different study involved the YN1 field strain, whose ORF3 gene was found to encode an early stop codon at position 145 after serial propagation in Vero cells for 200 passages ([@bib0125]). Full-length sequences at passages 15, 30, 60, 90, 144, and 200 had been analyzed, with no changes observed for the NSP2, NSP4--7, NSP10, NSP12 and NSP13 genes during the Vero cell adaptation process. Identified mutations included 9--26 amino acid changes in ORF 1a/b and S, an early termination codon in ORF3, and 1--3 amino acid changes in the E, M and N proteins. The passage 15 virus YN15 had 8 amino acid changes in the ORF3 gene and had already gained the early termination codon. When field-isolated YN1 and cell-adapted YN15 were characterized for pathogenicity in piglets, infected piglets from both groups showed classic and similar signs of infection, with watery diarrhea and emaciation. Therefore, acquisition of a truncated ORF3 by YN1 progeny appears to be more important for cell adaptation than attenuation.

Truncation of ORF3 hints at its dispensability in cell culture. This has been confirmed by reverse genetics, where a recombinant PEDV based on attenuated DR13 (which encodes an ORF3 with a 17-amino acid deletion) was successfully rescued by targeted RNA recombination ([@bib0360]). Likewise, our own study generated reverse genetics-derived AVCT12, which contains a C-terminal deletion of the S gene resulting in disruption of the ORF3 start codon and absence of the ORF3 protein ([@bib0265]). While this virus grew to the same titers as the original virus, reverse genetics virus with a restored ORF3 gene could not be rescued. These results suggest that ORF3 may negatively affect viral growth in cell culture. On the other hand, an infectious molecular clone was recently generated based on the virulent PEDV strain PC22A, which possesses an intact ORF3 gene ([@bib0040]). And while disruption of the ORF3 with red fluorescent protein did not increase viral titer, both wild-type and ORF3-deleted recombinant viruses replicated to titers around 2--3 log less than recombinant AVCT12. Interestingly, regardless of the presence of ORF3, all inoculated piglets succumbed to illness or were euthanized due to illness at their final time points. The notable differences between these two studies are likely due to viral genetic background---our reverse genetics report focused on the use of an SM98 vaccine-like strain, which may have other adaptations that render ORF3 dispensable, and even detrimental.

The correlation between mutations in the ORF3 gene and cell adaptation of field isolates after cell culture has raised many questions about its function. Based on the relative ORF3 conservation among coronaviruses ([@bib0665]), it may be possible to glean clues from other coronaviruses. [Table 4](#tbl0020){ref-type="table"} lists the various ORF3 homologs and their known characteristics. The more extensively studied SARS-CoV ORF3a appears to have multiple functions, including ion channel activity ([@bib0390]) and induction of apoptosis ([@bib0100]). With structural studies revealing the tetramerization and membrane localization possibly indicative of ion channel properties ([@bib0390]), ORF3a was tested for ion channel function by injection of ORF3a RNA into *Xenopus* oocytes. The results suggested that ORF3a forms a potassium-sensitive channel. In a separate study, FRhk-4 cells transfected with siRNA targeting ORF3a prior to infection with SARS-CoV showed a significant decrease in viral release ([@bib0100]). Furthermore, mutations interfering with potassium channel activity abolished caspase-dependent apoptosis. Therefore, the ion channel activity of ORF3a may affect SARS-CoV release and its pro-apoptotic properties.Table 4Characteristics of ORF3 homologs in coronaviruses.Table 4CoVORFLength\
(aa)FunctionSubcellular localizationSARSORF3a274Ion channel ([@bib0390]) and pro apoptotic ([@bib0100]) activitiesCytoplasm, plasma membrane ([@bib0670]) and Golgi apparatus ([@bib0810])TGEVORF3b244Viral pathogenicity ([@bib0750])UnknownPEDVORF3224Ion channel activity ([@bib0735]), prolongs S phase and facilitates vesicle formation ([@bib0785])Cytoplasm and punctuate vesicle-like structures in the cytoplasm ([@bib0785]) and unpublished data)HCoV-229EORF4a133Ion channel activity and acts as viroporin ([@bib0820])Endoplasmic reticulum/Golgi intermediate compartment ([@bib0820])HCoV-NL63ORF3225Structural viral protein ([@bib0465])Endoplasmic reticulum/Golgi intermediate compartment ([@bib0465])

A computational model using five different programs predicted four transmembrane regions for PEDV ORF3 (TM1 at Q40--S63, TM2 at R75--I97, TM3 at Y116--Y139, and TM4 at G150--I173), with ORF3 assembling to form a homotetrameric protein complex with a central pore ([@bib0735]). This model offers a structural prediction distinct from that predicted by SwissProt His, and this discrepancy will need to be resolved by structural studies in the future. Nevertheless, it is suggestive that PEDV ORF3 may also possess ion channel function.

The first attempt to directly study PEDV ORF3 function involved expression of ORF3 from parental and cell-adapted CV777 in *E. coli* as a heterodimeric fusion protein ([@bib0585]). The full-length parental ORF3 was expressed poorly compared to the truncated form from the cell-adapted strain, which the authors suggested may be indicative of a degree of functional toxicity. Expression of CV777 ORF3 in *Xenopus laevis* and *Saccharomyces cerevisiae*, however, did reveal potassium ion channel function, along with the importance of residue Y170 for such activity ([@bib0735]). In comparison, truncated ORF3 from cell-adapted CV777 lacked this ion channel activity. Virus production was additionally observed to be reduced after infection when cells were treated with siRNA to silence the ORF3 gene, suggesting that ORF3 may affect viral replication like SARS-CoV ORF3a. A more recent study used a Vero cell line stably expressing ORF3 (Vero-ORF3) to assess the protein's impact on the host cell ([@bib0785]). Aside from its cytoplasmic localization, the observed prolongation of the cell cycle S phase and the appearance of large double-membrane vesicles possibly acting as sites of viral replication ([@bib0225], [@bib0540], [@bib0630]) together suggest that ORF3 may help promote viral growth. Indeed, ORF3 increased viral titers of attenuated viruses, although it had no effect on the non-attenuated field isolate, indicating that ORF3 can play a role in viral replication *in vitro*.

The data so far are conflicting regarding the role of ORF3 and its importance for viral replication and pathogenicity both *in vivo* and *in vitro*. This is unsurprising given its nature as an accessory protein, whose role and importance can vary depending upon virus and host cell contexts. It will be essential to accumulate a larger pool of data, and the application of reverse genetics will help control variation within each study, as well as enable analysis of the impact of other viral proteins in conjugation with ORF3 in mediating PEDV adaptation and pathogenicity.

8. N and PEDV pathogenicity {#sec0065}
===========================

N proteins of coronaviruses carry out multiple functions during the viral life cycle. The most abundant structural protein in virions, the primary function of N is to organize the viral genome, relying on its RNA binding and self-multimerization properties. Additional functions include virus assembly, cell cycle regulation, apoptosis induction, host stress response, translational shutoff and immune system interference ([@bib0425]). N has therefore been an attractive target for antiviral research, especially for coronaviruses that are human pathogens such as SARS-CoV and MERS-CoV.

Following the resurgence in severe PEDV epidemics, research on PEDV N has started to gain momentum. Studies on N have focused on its possible roles in PEDV pathogenesis, regulation of host cell environment and immune evasion. Using CV777 infection in porcine intestinal epithelial cells (IECs), Cao et al. demonstrated that active PEDV replication could induce gene expression under the NF-κB promoter in a dose-dependent manner ([@bib0090]). With co-transfection experiments, they identified N, especially the immuno-dominant central region, as responsible for PEDV-dependent NF-κB activation through Toll-like receptors 2, 3 and 9. This is in line with a previous report that N from a PEDV strain isolated in Shaanxi province could activate NF-κB ([@bib0770]). In IECs stably transfected with a pGFP-N expression vector, upregulation of NF-κB, along with an endoplasmic reticulum (ER) chaperone GRP78 and IL-8, was observed compared to IECs expressing GFP alone. In contrast, in transfected HEK 293T cells, N derived from strain AJ 1102 inhibited promoter activation of NF-κB, IFN-β and IRF3 ([@bib0165]). This study also observed inhibition of Sendai virus-induced IFN-β production and IFN-stimulated gene expression, suggesting a role for N as an interferon antagonist. The authors further demonstrated that N interacts with TBK1 and in turn inhibits TBK1 phosphorylation of IRF3.

Even cellular localization of N is still debatable. Xu et al. suggested that N could localize to the ER, leading to ER stress and cell cycle arrest ([@bib0770]). They specifically stated that, in their experimental setup of IECs stably expressing N fused with a C-terminal EGFP, they did not observe N in the nucleolus of the cells. However, using CV777 infection and expression of an N-GFP fusion protein in Vero E6 cells, Shi et al. observed predominant cytoplasmic localization of PEDV N, with a certain fraction in the nucleolus ([@bib0600]). They further identified the nucleolar localization and nuclear export signals of N, although the importance of nucleocytoplasmic shuttling of N was not clear.

Together, these results present a likely incomplete and complex story for the roles of N in PEDV pathogenesis and host cell manipulation. These experiments were conducted with different PEDV strains and in various cell lines, possibly giving rise to discrepancies. Another important aspect is the lack of information on how PEDV infection or the viral life cycle is affected should any of these proposed functions of N be altered. Although they can help delineate the role of N in PEDV pathogenicity and identify important molecular features, experiments in the context of transfection should be complemented with rigorous tests for physiological relevance in the context of PEDV infection. For this purpose, reverse genetics platforms for PEDV where mutations of N could be easily introduced are useful tools for addressing these issues.

The reverse genetics platform will also allow further exploration into other biochemical curiosities present in N. For example, N contains three intrinsic disorder regions (IDRs) flanking its structural portions. Unlike other coronaviruses whose IDRs comprise serines and arginines (SR-rich; ([@bib0260])), IDRs in PEDV N consist of several repeats of asparagines (N-rich). Reports have suggested that the SR-rich IDRs participate in N oligomerization, offer additional RNA binding sites, and allow enough flexibility for the arrangement of viral ribonucleoprotein complex structures ([@bib0105], [@bib0395]). Nevertheless, it is unknown whether PEDV's N-rich IDRs would behave similarly. Experiments with reverse genetics-derived PEDV variants carrying N mutants with IDRs of varying length and amino acid composition could provide very useful insights into virus fitness, replication cycle and virulence.

9. Challenges in PEDV vaccine design {#sec0070}
====================================

Given the recurrent worldwide outbreaks of PEDV since its first discovery, a number of PEDV vaccines are now commercially available. Vaccine companies in Korea (Komipharm and Daesung), Japan (Nisseiken and Kaketsuken) and China produce PEDV vaccines for the Asian market. And soon after PEDV was introduced into the United States, two commercial vaccines were rapidly developed and granted conditional USDA license to contain the epidemic. The first vaccine developed by Harrisvaccine and Merck, *iPED*+, uses alphavirus replicon vaccine technology ([@bib0715]). The other, marketed by Zoetis, is based on the inactivated/killed virus platform.

Most, if not all, PEDV vaccines are designed for parenteral immunization, which may provoke skepticism among users regarding the efficacy of these vaccines against enteric pathogens like PEDV. It is commonly known that newborn piglets, though immunocompetent, are usually unable to mount primary immune responses in time to prevent disease onset, especially those associated with acute viral infection. They heavily rely on maternal passive immunity obtained from colostrum and milk, as the placentally transferred antibodies during gestation are not sufficient to confer disease protection ([@bib0290], [@bib0690]). Given that PEDV infects its hosts primarily by directly invading enterocytes lining the intestinal villi and the virus does not require systemic spread, it is likely that mucosal immunity, particularly secretory IgA, is responsible for virus neutralization and disease protection as opposed to the IgG predominantly found in sera of sows vaccinated via the parenteral route. Although PEDV-specific IgG may be present in high amounts in colostrum at parturition in sows intramuscularly vaccinated by PEDV live vaccines ([@bib0535]), protection duration tends to be very short due to rapid decline of colostrum production in post-parturient sows ([@bib0295]).

Several lines of evidence support the notion that oral immunization of pregnant sows with live PEDV is essential for stimulating adequate lactogenic immunity for piglet protection. It has been shown recently that sows orally fed with intestinal homogenates obtained from clinically affected piglets exhibit significantly higher levels of milk anti-PEDV neutralizing antibodies compared to those intramuscularly immunized by the iPED+ vaccine ([@bib0580]). Likewise, Paudel et al. showed that oral administration of live attenuated PEDV strain DR-13 to pregnant sows reduces the mortality rate of nursing piglets ([@bib0535]). A different study demonstrated that sows previously exposed to a mild strain of PEDV can passively transfer sufficient lactogenic immunity to piglets for protection against virulent PEDV exposure ([@bib0220]). And, in line with studies in PEDV-infected sows, pregnant sows fed with TGEV also exhibit substantially elevated levels of IgA antibodies in milk that confer passive protection against virulent TGEV to piglets ([@bib0060], [@bib0055], [@bib0110]). In contrast, sows vaccinated with recombinant subunit vaccines based on the TGEV S protein provide inadequate protective immunity against similar challenge ([@bib0505]).

Efficacy of live oral vaccines depends largely on the ability of PEDV to infect and replicate in swine enterocytes. Accumulating data seem to suggest that adaptation of PEDV to cell culture affects the efficacy of viruses used as oral vaccines. For instance, sows orally inoculated with parental DR13 displayed higher immune responses when compared to those fed with virus cultured in Vero cells to passages 75 or 90 ([@bib0635]). Likewise, Chen et al. recently performed virulence experiments by orally inoculating nursing piglets with either a low- (YN15) or high-passage number (YN144) variant of the virulent YN1 strain ([@bib0125]). They demonstrated that, while all YN15-infected piglets succumbed to severe diarrhea, those infected with YN144 showed no detectable clinical signs. Immunohistochemical analyses of intestinal samples from YN15- and YN144-infected piglets clearly indicated that YN144 barely infected swine enterocytes. Notably, results from others and our laboratory also suggest that cell-adapted PEDV strains infect and replicate in swine enterocytes less efficiently than in Vero cells ([@bib0135]). While it is currently not known exactly how adaptation in cells of non-swine origin can affect the ability of PEDV to initiate infection in swine cells, it is clear that *in vivo* infection of swine enterocytes is a prerequisite for an effective PEDV vaccine.

To develop such effective PEDV vaccines, not only should the seed vaccine maintain high growth *in vitro*, but virus adaptation in host cells must also be minimized without compromising attenuation. With these considerations in mind, the reverse genetics systems of PEDV available to-date offer great potential for novel vaccine development. With more insight into differences between field-isolated and cell-adapted variants, it will be possible to genetically manipulate the infectious clone of a high-growth PEDV to switch its tropism preference from monkey (Vero) to swine cells. Investigation of Vero and swine enterocyte entry by recombinant viruses may help identify key residues involved in cell adaptation, which should in turn provide insightful information for augmenting entry of cell-adapted PEDV into intestinal cells. Particularly encouraging is the ease in changing viral tropism by generating the reverse genetics-derived coronavirus bearing chimeric or mutant S genes ([@bib0320], [@bib0435], [@bib0440], [@bib0555]), with Phillips et al. analyzing changes in MHV neurotropism conferred by the S of mildly versus highly neurovirulent strains ([@bib0555]). Similarly, PEDV with chimeric S can be used to identify the determinants of viral tropism at the nucleotide level, paving the way towards the engineering of S to harbor domains necessary for enterocyte entry while maintaining the necessary antigenic sites for eliciting humoral protective immunity.

While it is not clearly elucidated what genetic components of cell-adapted PEDV are responsible for its attenuation, changing tropism to favor swine intestinal cells may affect virulence. If so, based on the well-characterized SARS-CoV candidate vaccines ([@bib0475], [@bib0575]), a number of approaches could be employed to attenuate a potential PEDV vaccine. The 2′O-methyl-transferase (2′O-MTase), NSP16, has been shown to be an attractive target for attenuation of many coronaviruses ([@bib0430]). Though not yet studied in detail, genetic modification of PEDV NSP16 may provide a useful tool for virus attenuation. SARS-CoV with a disrupted or mutated E gene has also been generated and was shown to be highly attenuated *in vivo* ([@bib0475], [@bib0575]). While it is possible for SARS-CoV with a deleted E gene to regain virulence upon serial passaging, further manipulation of the virus genome such as truncating the NSP1 protein can help maintain the attenuated phenotype of the virus ([@bib0270]). Indeed, the coronavirus NSP1 has been proposed to play a major role in determining the virulence of many coronaviruses, primarily by interfering with the host innate immune response ([@bib0835]). A recent study showing that PEDV NSP1 can disrupt type I interferon signaling by degrading the CREB-binding protein (CBP) ([@bib0825]) supports the possibility of modifying this protein for PEDV attenuation.

10. Concluding remarks {#sec0075}
======================

With the advent of reverse genetics systems for the genetic manipulation of PEDV genomes, these technologies promise to revolutionize PEDV research. In this review, we have described PEDV reverse genetic systems as well as past and current applications of this technology towards bettering our understanding of PEDV. Furthermore, we have discussed the many unanswered questions that we deem critical for advancing our understanding of this economically important pathogen, and how reverse genetics may be the tool to provide the much-needed answers. The integration of advances in reverse genetics approaches, animal testing, and novel engineered host cells will be critical for fostering the development of next-generation vaccines to tackle future PEDV and possibly other coronavirus outbreaks.
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[^1]: APN, aminopeptidase N; DMEM, Dulbecco's modified Eagle's medium; DMEM-F12, Dulbecco's modified Eagle's medium --Ham's F12 mixture; EMEM, Eagle's minimal essential medium; MEM, Minimal essential medium; FBS, fetal bovine serum; HEPES, *N*-2-hydroxyethylpiperazine-*N*'-2-ethanesulfonic acid.
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